Investment analysts at StockNews.com began coverage on shares of Amarin (NASDAQ:AMRN – Get Free Report) in a research note issued on Sunday. The firm set a “sell” rating on the biopharmaceutical ...

Activist investor Sarissa Capital won control over Amarin’s board two years ago on a fierce campaign of stirring up value for ...

Amarin Corp. (AMRN) gains 6.3% as major shareholders push for a strategic review to recover value after a dramatic stock drop ...

While we appreciate Sarissa Capital Management's ("Sarissa") involvement and commitment to the Company, we believe shareholders would be best served by the Board immediately conducting a strategic ...

Corporation announced that additional in vitro mechanistic data with eicosapentaenoic acid, EPA, will be presented at the ...

Q4 2024 Earnings Call Transcript March 12, 2025 Amarin Corporation plc beats earnings expectations. Reported EPS is $-0.03, ...

Amarin Corp PLC (AMRN) reports strong international growth and strategic advancements despite US market pressures.

Operator Welcome to Amarin Corporation's conference call to discuss its fourth-quarter and full-year 2024 business update and ...

Amarin Corporation plc (NASDAQ: AMRN), today announced its intent to effect a ratio change on its American Depositary Shares ("ADS") from ...

Amarin (AMRN) stock falls even as the company beats Q4 forecasts amid its plans to implement a 20:1 ADS ratio change to maintain Nasdaq listing. Read more here.

No fractional new ADSs will be issued in connection with the Ratio Change. Rather, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank, and the net cash proceeds ...

Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024 Cash Position of $294.2 Million -- -- Fourth Quarter and Full-Year 2024 Performance Reflects Benefits of ...